Device Trial Radar · NCT04153292
The ENCIRCLE Trial
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
786
Actual
Start
Nov 12, 2020
Primary completion
Oct 10, 2027
Study completion Oct 10, 2031
Sponsor
- Lead sponsor
- Edwards LifesciencesPublic (EW)
- Sponsor type
- Industry
- First posted
- Nov 6, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Conditions
- Mitral Regurgitation
- Mitral Valve Insufficiency
Interventions
SAPIEN M3 valve and dockDevice
During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Non-hierarchical composite of death and heart failure rehospitalizationTime frame: 1 year
Locations
54 sites in 6 countries. Site status is shown where the registry gives one.
Heart Center Hospital
Huntsville, Alabama
Banner University Medical Center
Phoenix, Arizona
Saint Josephs Hospital Medical Center Dignity Health
Phoenix, Arizona
51 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.